Publications by authors named "Matthias Pinter"

Claim this Profile
R
Reply: Immortal time bias in the management of patients with HCC who achieved CR following immunotherapy-based systemic therapy.
Bernhard Scheiner, Matthias Pinter

Hepatology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis.
Lorenzo Lani, Bernhard Scheiner, Matthias Pinter, Thomas Reiberger

Liver Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, Ciro Celsa, Claudia A M Fulgenzi, Matthias Pinter

JHEP Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
Bernhard Scheiner, Matthias Pinter

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death.
Mathias Jachs, Tânia Carvalho, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, Matthias Pinter

Aliment Pharmacol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular carcinoma in people living with HIV.
Claudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, Matthias Pinter

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomics-based prediction of HCC response to atezolizumab/bevacizumab.
Isaac Rodriguez, Abhinay Vellala, Timo Itzel, Jimmy Daza, Michael Vácha, Matthias Pinter

Oncol Lett· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking Aggravates Inflammation, Fibrogenesis, Angiogenesis and Cancer Risk in Patients With Cirrhosis.
Nina Dominik, Benedikt Simbrunner, Bernhard Scheiner, Michael Schwarz, Lukas Hartl, Matthias Pinter

Liver Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil Extracellular Traps Are Not Linked to Decompensation, ACLF, or Death in Clinically Stable Patients With ACLD.
Lorenz Balcar, Bernhard Scheiner, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, Matthias Pinter

Liver Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, Gwangil Kim, Masoud Tafavvoghi, Matthias Pinter

J Immunother Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Lorenz Kocheise, Jan Kempski, Yunhe Tang, Lorenz Balcar, Victoria Berger, Matthias Pinter

Ann Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D'Alessio, Matthias Pinter

JHEP Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
Yoon Jun Kim, Philippe Merle, Richard S Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Matthias Pinter

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
Bernhard Scheiner, Beodeul Kang, Lorenz Balcar, Iuliana-Pompilia Radu, Florian P Reiter, Matthias Pinter

Hepatology· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.
Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Matthias Pinter

Aliment Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.
Matthias Pinter, Claudia A M Fulgenzi, David J Pinato, Bernhard Scheiner

Gut· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Imaging Parameters for Assessment of Hepatocellular Carcinoma Using Photon-Counting Detector Computed Tomography-Impact of Reconstruction Kernel and Slice Thickness.
Anna Szelenyi, Philipp Stelzer, Christian Wassipaul, Jakob Kittinger, Andreas Strassl, Matthias Pinter

Tomography· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Matthias Pinter

Lancet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.
Stefan Munker, Isaac Rodriguez, Kathrin Bernhart, Najib Ben Khaled, Merve Findik, Matthias Pinter

J Hepatocell Carcinoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Matthias Pinter

J Hepatocell Carcinoma· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
Katharina Pomej, Adrian Frick, Bernhard Scheiner, Lorenz Balcar, Larissa Pajancic, Matthias Pinter

PLoS One· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.
Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, Fabian Artusa, Bernhard Scheiner, Matthias Pinter

JHEP Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.
Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Matthias Pinter

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.
Meng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, Alessio Cortellini, Ciro Celsa, Matthias Pinter

JHEP Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma.
Iuliana Pompilia Radu, Bernhard Scheiner, Jonas Schropp, Maria Gabriela Delgado, Birgit Schwacha-Eipper, Matthias Pinter

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis